ESR1 alterations and metastasis in estrogen receptor positive breast cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Endocrine therapy is crucial for estrogen receptor-positive (ER+) breast cancer.
• Therapeutic resistance and metastasis are common challenges in ER+ breast cancer treatment.
• The estrogen receptor alpha (ESR1) gene is implicated in resistance and metastatic progression.

Purpose of the Study:

• To review pre-clinical and clinical evidence on ESR1 alterations in ER+ breast cancer.
• To explore how ESR1 alterations contribute to therapeutic resistance and metastasis.
• To identify potential therapeutic opportunities arising from ESR1 alterations.

Main Methods:

• Literature review of pre-clinical studies.
• Analysis of clinical evidence on ESR1 alterations (amplification, mutations, rearrangements).
• Examination of the role of ESR1 dysregulation in metastatic biology.

Main Results:

• ESR1 alterations, including amplification, point mutations, and genomic rearrangements, are linked to treatment resistance.
• These ESR1 alterations are associated with the metastatic potential of ER+ breast cancer.
• Dysregulation of ESR1 contributes to the development of lethal, metastatic disease.

Conclusions:

• ESR1 alterations are key drivers of resistance and metastasis in ER+ breast cancer.
• Understanding ESR1 genetic changes is critical for developing novel therapeutic strategies.
• Targeting ESR1 alterations may improve outcomes for patients with metastatic breast cancer.